Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Price Vision Group

Neither a doctor nor a teaching hospital

Research payments

$338,081

173 payments

Through program year 2025, Price Vision Group is reported as receiving $338,081 in research payments, across 173 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $92,849 14
2024 Research $1,000 1
2023 Research $1,000 1
2022 Research $93,371 19
2021 Research $97,335 121
2020 Research $19,482 15
2019 Research $33,045 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Alcon Research LLC $112,435 147 payments
  2. AbbVie, Inc. $98,752 9 payments
  3. Oyster Point Pharma, Inc. $89,174 12 payments
  4. Aerie Pharmaceuticals, Inc. $33,045 2 payments
  5. Bausch & Lomb Americas Inc. $4,675 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Pivotal Trial of WaveLight EX500 Excimer Laser System for the Correction of Myopia with and without Astigmatism Using InnovEyes in Conjunction with InnovEyes sightmap $108,434 145 payments
  2. Currently available treatments for presbyopia (old eye) include nonsurgical options (spectacles or contact lenses) and surgical options, however, each has its own risks and limitations. The purpose of this study is to evaluate how effective AGN-190584 is in treating presbyopia compared to vehicle (placebo). $66,696 3 payments
  3. Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) $66,148 8 payments
  4. Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia (VEGA-3) $23,026 4 payments
  5. Prospective randomized study to determine whether use of Rhopressa accelerates corneal clearing after removal of Descemet membrane for treatment of Fuchs dystrophy $20,600 1 payment
  6. A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily (Virgo) $19,541 3 payments
  7. A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of BID Dosing of AGN-190584 in Subjects with Presbyopia $12,516 3 payments
  8. Prospective randomized study to determine whether use of Rhopressa can ammeliorate corneal edema associated with Fuchs dystrophy $12,445 1 payment
  9. Ic-8 Apthera Iol New Enrollment Post Approval Study $4,675 3 payments
  10. Pivotal Trial of InnovEyes (Ray Tracing) LASIK for myopia with or without astigmatism (Refractive Suite Enhancement II) $4,001 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record